While Synthetic Biologics Inc (NYSEMKT:SYN) investors are waiting for phase 2 results of the company’s flagship drug SYN-004, Griffin analyst Keith Markey is out with a research note, reiterating a …
On Tuesday morning, Synthetic Biologics Inc (NYSEMKT:SYN) made a positive stride with the completion of an End of Phase 2 meeting with the FDA for …
Synthetic Biologics Inc Synthetic Biologics Inc (NYSE:SYN) shareholders are celebrating today after the biotech company reported above-consensus first-quarter results, sending shares up 23%. …
In a research report issued Friday, FBR analyst Edward White reiterated an Outperform rating on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with a price …
In a research report released Friday, FBR analyst Edward White initiated coverage on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with an Outperform rating …
There’s never a dull moment in the biotechnology sector as analysts weigh in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in light of a …
While U.S.
Amazon.com, Inc.
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today …
